Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R.
Kobayashi Y, et al. Among authors: saito k.
Int J Hematol. 2009 May;89(4):460-469. doi: 10.1007/s12185-009-0298-1. Epub 2009 Apr 10.
Int J Hematol. 2009.
PMID: 19360457
Clinical Trial.